Physician profile
Morgan Kirkpatrick
NPI 1457915795
$951.78
in general payments reported to CMS, 2019-2025
10 companies · $544 in 2025
The $544 reported for 2025 was more than what 82% of Addiction Medicine (Family Medicine) providers received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $73.34 · 2023: $231 · 2024: $104 · 2025: $544.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $878.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $878.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $253.17 | 2025 | Brixadi |
| Astellas Pharma US INC | $174.82 | 2023-2024 | Veozah |
| Alkermes, INC. | $136.17 | 2025 | Vivitrol |
| Astrazeneca Pharmaceuticals Lp | $100.48 | 2023 | Farxiga |
| Indivior INC. | $100.17 | 2025 | Sublocade |
| Organon LLC | $97.23 | 2022-2025 | Nexplanon |
| Novo Nordisk INC | $43.68 | 2024 | Wegovy |
| Merck Sharp & Dohme LLC | $15.46 | 2025 | Gardasil 9, Capvaxive, Rotateq |
| Supernus Pharmaceuticals, INC. | $15.31 | 2024 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $15.29 | 2025 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morgan Kirkpatrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.